Kilty Cormac G, Keenan Joe, Shaw Martin
Biotrin International, 93 The Rise, Mount Merrion, Dublin, Ireland.
Expert Opin Drug Saf. 2007 Mar;6(2):207-15. doi: 10.1517/14740338.6.2.207.
Histopathology is the gold standard when defining toxicological effects, but it is invasive, time consuming and expensive. Using biomarkers linked to distinct, defined cell types and tissues may provide a direct link to histopathology without its drawbacks and it also provides increased sensitivity and specificity. Furthermore, as histological testing is often impractical in human subjects, using biomarkers with a known histological distribution may fill the need of localising toxic injury to distinct organs or tissues. This paper discusses how, by using biomarkers with a known cellular origin (histologically defined biomarkers), toxic effects may be found earlier and at lower doses of compound, leading to potential savings in drug development.
组织病理学是定义毒理学效应的金标准,但它具有侵入性、耗时且昂贵。使用与不同的、明确的细胞类型和组织相关的生物标志物,可能会提供与组织病理学的直接联系,而没有其缺点,并且还能提高敏感性和特异性。此外,由于组织学检测在人体受试者中往往不切实际,使用具有已知组织学分布的生物标志物可能满足将毒性损伤定位到不同器官或组织的需求。本文讨论了如何通过使用具有已知细胞起源的生物标志物(组织学定义的生物标志物),在更低的化合物剂量下更早地发现毒性效应,从而在药物开发中节省成本。